Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of Zilovertamab Vedotin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Diffuse Large B Cell Lymphoma, which is a form of non-Hodgkin’s lymphoma. This study is specifically for patients whose cancer has returned or has not responded to previous treatments. The treatment being tested in this study is a medication called Zilovertamab vedotin, also known by its code name MK-2140. This medication is given as a solution through an intravenous infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to evaluate the safety and effectiveness of Zilovertamab vedotin in treating patients with this type of lymphoma. Participants in the study will receive the medication and will be monitored to see how their cancer responds to the treatment. The study will also look at how long any positive effects last and whether there are any side effects. Some participants may receive a placebo, which is a substance with no active medication, to compare the results.

The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The goal is to gather information that could help improve treatment options for people with Diffuse Large B Cell Lymphoma in the future. Participants and healthcare providers will be aware of the treatment being given, as this is an open-label study, meaning there is no blinding or concealment of the treatment from those involved.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes reviewing medical history and conducting necessary tests to ensure the diagnosis of diffuse large B-cell lymphoma (DLBCL) is accurate.

    The assessment will also evaluate previous treatments and determine if the condition has progressed after at least two lines of prior therapy, including a multiagent regimen with an alkylating agent, anthracycline, and anti-CD20 monoclonal antibody.

  2. Step 2

    Treatment plan discussion

    A healthcare provider will discuss the treatment plan, which involves the administration of zilovertamab vedotin.

    The treatment will be given as an intravenous infusion, which means the medication will be delivered directly into the bloodstream through a vein.

  3. Step 3

    Treatment administration

    The medication, zilovertamab vedotin, will be administered as a solution for infusion. The specific dosage and frequency will be determined by the healthcare provider based on individual health needs.

    The duration of the treatment will be outlined by the healthcare provider, and regular monitoring will be conducted to assess the response to the treatment.

  4. Step 4

    Regular monitoring

    Throughout the trial, regular monitoring will be conducted to evaluate the effectiveness of the treatment and to check for any side effects.

    This includes assessments based on the Lugano Response Criteria, which is a set of guidelines used to measure the response of lymphoma to treatment.

  5. Step 5

    Follow-up assessments

    Follow-up assessments will be scheduled to determine the objective response rate and the duration of response to the treatment.

    The healthcare provider will also monitor for any adverse events and determine if any adjustments to the treatment plan are necessary.

Who can join the trial?

10 criteria

  • Must have Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or did not respond to previous treatments.
  • Must have tried at least two different treatments before, including a stem cell transplant or be unable to have one.
  • Must have received a treatment plan that included an alkylating agent (a type of chemotherapy), anthracycline (another type of chemotherapy), and an anti-CD20 monoclonal antibody (a medicine that targets specific cells).
  • Must have a confirmed diagnosis of DLBCL through a tissue sample.
  • Must have DLBCL that can be measured by scans according to specific criteria.
  • Should have either not responded to CAR-T cell therapy (a type of treatment that uses modified immune cells) or be unable to receive it for any reason.
  • Must have a life expectancy of at least 3 months.
  • Must have a performance status score between 0 to 2, which means being fully active or having some limitations but able to care for oneself.
  • Must have organs that are working well enough to participate in the study.
  • Both men and women can participate.

Who cannot join the trial?

5 criteria

  • Patients who have not failed prior therapies for Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma) cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not part of the specified clinical trial groups cannot participate.
  • Patients who are not male or female cannot participate.
  • Patients who are not considered part of a vulnerable population cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Zilovertamab Vedotin (MK-2140) is a medication being studied for its potential to treat a type of cancer called diffuse large B-cell lymphoma, which is a form of non-Hodgkin lymphoma. This medication is designed to target and attach to specific proteins found on the surface of cancer cells. Once attached, it delivers a toxic substance directly into the cancer cells, which may help to kill them or stop them from growing. The goal of using this medication in the trial is to see how well it works in shrinking the tumors and to assess its safety for patients who have not responded to other treatments or whose cancer has returned.

What is already known about the treatment

Zilovertamab Vedotin – Zilovertamab Vedotin is administered intravenously, meaning it is given through a vein. It is currently being studied in clinical trials for its effectiveness and safety in treating Diffuse Large B-Cell Lymphoma, a type of non-Hodgkin’s lymphoma, especially in patients who have not responded to previous treatments. This medication works by targeting specific proteins on cancer cells, delivering a toxic substance directly to them, which helps to kill the cancer cells. It is classified as an antibody-drug conjugate, a type of targeted cancer therapy.

Investigated diseases

Diffuse Large B Cell Lymphoma – Diffuse Large B Cell Lymphoma is a type of non-Hodgkin's lymphoma characterized by the rapid growth of large B cells in the lymphatic system. It typically begins in the lymph nodes but can also affect other organs. The disease progresses quickly, with the abnormal B cells spreading throughout the body. As the lymphoma advances, it can cause swelling of the lymph nodes, fatigue, fever, and weight loss. The rapid proliferation of these cells can lead to the formation of tumors in various parts of the body. The progression of the disease can vary, with some cases advancing more rapidly than others.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2022-501243-33-00Protocol codeMK2140-004Estimated enrolment134 patientsSponsorMerck Sharp & Dohme LLC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.